Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Male gender, active smoking and previous intestinal resection are risk factors for post-operative endoscopic recurrence in Crohn's disease: results from a prospective cohort study.
Auzolle C, Nancey S, Tran-Minh ML, Buisson A, Pariente B, Stefanescu C, Fumery M, Marteau P, Treton X, Hammoudi N; REMIND Study Group Investigators; Jouven X, Seksik P, Allez M. Auzolle C, et al. Aliment Pharmacol Ther. 2018 Nov;48(9):924-932. doi: 10.1111/apt.14944. Epub 2018 Aug 20. Aliment Pharmacol Ther. 2018. PMID: 30126030
Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID).
Gagnière C, Bourrier A, Seksik P, Gornet JM, DeWit O, Nancey S, Altwegg R, Abitbol V, Laharie D, Reenaers C, Buisson A, Pariente B, Viennot S, Vuitton L, Stefanescu C, Marteau P, Bouguen G, Cosnes J, Amiot A; GETAID INFOPRO study group. Gagnière C, et al. Aliment Pharmacol Ther. 2018 Oct;48(7):713-722. doi: 10.1111/apt.14926. Epub 2018 Aug 2. Aliment Pharmacol Ther. 2018. PMID: 30069921 Free article.
Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study.
Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Vuitton L, Viennot S, Bouguen G, Abitbol V, Fumery M, Gagniere C, Bouhnik Y; OBSERV-IBD study group, the GETAID. Amiot A, et al. Aliment Pharmacol Ther. 2019 Jul;50(1):40-53. doi: 10.1111/apt.15294. Epub 2019 Jun 5. Aliment Pharmacol Ther. 2019. PMID: 31165509
One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.
Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Gagniere C, Bouhnik Y; OBSERV-IBD study group and the GETAID. Amiot A, et al. Aliment Pharmacol Ther. 2017 Aug;46(3):310-321. doi: 10.1111/apt.14167. Epub 2017 Jun 8. Aliment Pharmacol Ther. 2017. PMID: 28593685
Relationships of circulating CD4+ T cell subsets and cytokines with the risk of relapse in patients with Crohn's disease.
Duclaux-Loras R, Boschetti G, Flourie B, Roblin X, Leluduec JB, Paul S, Almeras T, Ruel K, Buisson A, Bienvenu J, Josson C, Jasnowski R, Legastelois S, Foussat A, Meunier C, Viret C, Rozieres A, Faure M, Kaiserlian D, Nancey S. Duclaux-Loras R, et al. Among authors: boschetti g. Front Immunol. 2022 Nov 4;13:864353. doi: 10.3389/fimmu.2022.864353. eCollection 2022. Front Immunol. 2022. PMID: 36405740 Free PMC article.
Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.
Tadbiri S, Peyrin-Biroulet L, Serrero M, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Gilletta C, Gagniere C, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Fumery M, Claudepierre P, Bouhnik Y, Amiot A; GETAID OBSERV-IBD study group. Tadbiri S, et al. Aliment Pharmacol Ther. 2018 Feb;47(4):485-493. doi: 10.1111/apt.14419. Epub 2017 Dec 18. Aliment Pharmacol Ther. 2018. PMID: 29250803
Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients.
Chapuis-Biron C, Bourrier A, Nachury M, Nancey S, Bouhnik Y, Serrero M, Armengol-Debeir L, Buisson A, Tran-Minh ML, Zallot C, Fumery M, Bouguen G, Abitbol V, Viennot S, Chanteloup E, Rajca S, Dib N, Parmentier AL, Peyrin-Biroulet L, Vuitton L; GETAID BioLAP Study Group. Chapuis-Biron C, et al. Aliment Pharmacol Ther. 2020 Apr;51(7):719-727. doi: 10.1111/apt.15665. Epub 2020 Feb 20. Aliment Pharmacol Ther. 2020. PMID: 32080886
153 results